DK0531410T3 - (+)-alfa-(2,3-Demethoxyphenyl)-1-(2-(4-fluorphenyl)ethyl)-4-piperidinmethanol - Google Patents
(+)-alfa-(2,3-Demethoxyphenyl)-1-(2-(4-fluorphenyl)ethyl)-4-piperidinmethanolInfo
- Publication number
- DK0531410T3 DK0531410T3 DK91910548.6T DK91910548T DK0531410T3 DK 0531410 T3 DK0531410 T3 DK 0531410T3 DK 91910548 T DK91910548 T DK 91910548T DK 0531410 T3 DK0531410 T3 DK 0531410T3
- Authority
- DK
- Denmark
- Prior art keywords
- piperidinemethanol
- fluorophenyl
- alpha
- ethyl
- demethoxyphenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53195490A | 1990-06-01 | 1990-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0531410T3 true DK0531410T3 (da) | 1995-01-30 |
Family
ID=24119769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK91910548.6T DK0531410T3 (da) | 1990-06-01 | 1991-04-30 | (+)-alfa-(2,3-Demethoxyphenyl)-1-(2-(4-fluorphenyl)ethyl)-4-piperidinmethanol |
Country Status (15)
Country | Link |
---|---|
US (6) | US5134149A (sv) |
EP (1) | EP0531410B1 (sv) |
JP (1) | JP2869512B2 (sv) |
KR (1) | KR100211713B1 (sv) |
AT (1) | ATE114467T1 (sv) |
AU (1) | AU652759B2 (sv) |
CA (1) | CA2083698C (sv) |
DE (1) | DE69105501T2 (sv) |
DK (1) | DK0531410T3 (sv) |
ES (1) | ES2067937T3 (sv) |
FI (1) | FI95370C (sv) |
GR (1) | GR3015087T3 (sv) |
HU (1) | HU213271B (sv) |
NO (1) | NO179250C (sv) |
WO (1) | WO1991018602A1 (sv) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004980A (en) * | 1990-06-01 | 1999-12-21 | Merrell Pharmaceuticals, Inc. | (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
ATE114467T1 (de) * | 1990-06-01 | 1994-12-15 | Merrell Dow Pharma | (+)-alpha-(2,3 dimethoxyphenyl)-1-(2- (fluorophenyl)ethyl>-4-piperidinmethanol. |
EP0796619A1 (en) * | 1996-03-21 | 1997-09-24 | Merrell Pharmaceuticals Inc. | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders |
US6028083A (en) * | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
GB9718712D0 (en) * | 1997-09-03 | 1997-11-12 | Merck Sharp & Dohme | Theraputic Agents |
GB9718833D0 (en) | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
KR100258018B1 (ko) * | 1997-12-23 | 2000-07-01 | 유승필 | 티클로피딘과 은행잎 추출물을 함유한 약제조성물 |
US20050261341A1 (en) * | 1998-03-13 | 2005-11-24 | Aventis Pharmaceuticals Inc. | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
TWI249526B (en) * | 1998-03-13 | 2006-02-21 | Aventis Pharma Inc | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
US6713627B2 (en) * | 1998-03-13 | 2004-03-30 | Aventis Pharmaceuticals Inc. | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
SE9801516D0 (sv) * | 1998-04-30 | 1998-04-30 | Maria Carlsson | M100907/4-Piperidinemethanol derivatives for autism |
GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
WO2000012090A1 (en) * | 1998-08-28 | 2000-03-09 | Aventis Pharmaceuticals Inc. | THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS |
US6939879B2 (en) * | 1998-08-28 | 2005-09-06 | Aventis Pharmaceuticals Inc. | Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia |
US6277864B1 (en) | 1998-08-28 | 2001-08-21 | Aventis Pharmaceuticals Inc. | Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders |
CN1160333C (zh) * | 1998-10-14 | 2004-08-04 | 阿温蒂斯药物公司 | 哌啶甲醇的酯和它们作为5ht2a受体拮抗剂mdl110907药物前体的用途 |
HU226586B1 (en) * | 1998-12-16 | 2009-04-28 | Aventis Pharma Inc | Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
US6455526B1 (en) * | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
FR2787328A1 (fr) | 1998-12-22 | 2000-06-23 | Sanofi Sa | Utilisation d'un antagoniste des recepteurs 5ht2a pour la preparation de medicaments utiles dans le traitement des ronflements et du syndrome de haute resistance ou de resistance des voies aeriennes superieures |
GB9901147D0 (en) | 1999-01-19 | 1999-03-10 | Merck Sharp & Dohme | Therapeutic agents |
US6465490B1 (en) | 1999-07-16 | 2002-10-15 | Aventis Pharmaceuticals Inc. | Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester |
AU769484B2 (en) * | 1999-07-16 | 2004-01-29 | Aventis Pharmaceuticals Inc. | Sulfuric acid mono-(3-((1-[2-(4-fluoro-phenyl)-ethyl)- piperidin-4-yl)-hydroxy-methyl)-2-methoxy-phenyl]ester |
DE19939756A1 (de) * | 1999-08-21 | 2001-02-22 | Merck Patent Gmbh | Piperidinalkohole |
ES2225031T3 (es) * | 1999-12-29 | 2005-03-16 | Pfizer Products Inc. | Compuestos de 3-((2-piperazinil-fenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos como antagonistas selectivos del receptor de 5-ht1d. |
CN100384836C (zh) * | 2000-02-29 | 2008-04-30 | 三菱制药株式会社 | 新型环状酰胺衍生物 |
GB0007907D0 (en) | 2000-03-31 | 2000-05-17 | Merck Sharp & Dohme | Therapeutic agents |
US20020099076A1 (en) * | 2000-05-25 | 2002-07-25 | Richard Scheyer D. | Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
US20030177248A1 (en) * | 2001-09-05 | 2003-09-18 | International Business Machines Corporation | Apparatus and method for providing access rights information on computer accessible content |
NZ537629A (en) * | 2002-07-19 | 2007-05-31 | Biovitrum Ab | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2A receptor-related disorders |
CN101099734A (zh) * | 2002-08-15 | 2008-01-09 | 惠氏公司 | 用于治疗体温调节机能障碍的5HT2a受体的激动作用 |
US7345096B2 (en) | 2002-10-15 | 2008-03-18 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
US7491723B2 (en) | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
US7419980B2 (en) | 2003-10-14 | 2008-09-02 | Wyeth | Fused-aryl and heteroaryl derivatives and methods of their use |
US7365076B2 (en) | 2003-10-14 | 2008-04-29 | Wyeth | Substituted aryl cycloalkanol derivatives and methods of their use |
US7524846B2 (en) | 2003-10-14 | 2009-04-28 | Wyeth | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
US7531543B2 (en) | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
US7402698B2 (en) | 2003-10-14 | 2008-07-22 | Wyeth | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use |
AU2004305563C1 (en) | 2003-12-11 | 2011-07-07 | Sunovion Pharmaceuticals Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20060069124A1 (en) * | 2004-09-07 | 2006-03-30 | Rao P S | Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases |
JP4975626B2 (ja) | 2004-09-30 | 2012-07-11 | エフ.ホフマン−ラ ロシュ アーゲー | 認知障害の処置用の組成物および方法 |
WO2009152647A1 (zh) * | 2008-06-20 | 2009-12-23 | 江苏恩华药业股份有限公司 | 芳烷基哌啶衍生物及其在制备镇痛、镇静药物中的应用 |
KR20140030267A (ko) | 2011-05-23 | 2014-03-11 | 사노피 | N알킬 그룹을 함유하는 중수소화된 화합물의 제조방법 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2833775A (en) * | 1951-08-17 | 1958-05-06 | Schering Corp | Substituted piperidines |
US3058979A (en) * | 1957-05-13 | 1962-10-16 | Smith Kline French Lab | New perfluoroalkylphenothiazine derivatives |
US3194733A (en) * | 1961-04-26 | 1965-07-13 | Olin Mathicson Chemical Corp | Phenothiazine compositions and method of treating mental disorders |
US3394131A (en) * | 1961-04-26 | 1968-07-23 | Squibb & Sons Inc | Acid esters of phenothiazine |
GB1316424A (en) * | 1969-05-20 | 1973-05-09 | Minnesota 3M Lab Ltd | Alpha-hydroxy-substituted-phenyl-alpha-2-piperidyl-methanols and process for the preparation thereof |
US3655676A (en) * | 1970-11-19 | 1972-04-11 | Smith Kline French Lab | 4-hydroxy-3-hydroxymethylphenyl-2-piperidinylcarbinols |
US4569941A (en) * | 1983-03-21 | 1986-02-11 | Usv Pharmaceutical Corp. | Method of using phenyl-alkylene-2-pyridyl derivatives to increase cardiac contractility in a mammal |
US4701461A (en) * | 1983-03-21 | 1987-10-20 | Usv Pharmaceutical Corporation | Substituted cyclic amines |
US4623728A (en) * | 1984-07-26 | 1986-11-18 | Pfizer Inc. | Intermediates for 1,3-disubstituted piperidine compounds as neuroleptic agents |
US4632929A (en) * | 1985-01-17 | 1986-12-30 | Usv Pharmaceutical Corp. | Method of hypertensive treatment using phenyl-alkylene-2-pyridyl derivatives |
US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
US4912117A (en) * | 1985-07-02 | 1990-03-27 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds |
US5169096A (en) * | 1985-07-02 | 1992-12-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl-piperidine-methanol derivatives |
US4783471A (en) * | 1985-07-02 | 1988-11-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine methanol derivatives and the uses thereof |
CA1280421C (en) * | 1985-07-02 | 1991-02-19 | Albert A. Carr | 1,4-disubstituted piperidinyl derivatives |
US5021428A (en) * | 1985-07-02 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds for the prophylactic treatment of migraine |
US4762842A (en) * | 1985-10-01 | 1988-08-09 | Eli Lilly And Company | Selective method for blocking 5HT2 receptors |
IT1205685B (it) * | 1987-05-26 | 1989-03-31 | Erregierre Spa | Processo per la preparazione di alfa-(alchilfenil)-4-(idrossi difenilmetil)-1-piperidina butanolo |
FI95572C (sv) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Förfarande för framställning av ett som läkemedel användbart piperidinderivat eller dess farmaceutiska salt |
US4877798A (en) * | 1987-11-23 | 1989-10-31 | Merrell Dow Pharmaceuticals Inc. | Treatment of fibromyalgia |
ZA888572B (en) * | 1987-11-23 | 1989-08-30 | Merrell Dow Pharma | Treatment of fibromyalgia |
JPH02138214A (ja) * | 1987-12-10 | 1990-05-28 | Merrell Dow Pharmaceut Inc | 不安を治療する方法 |
US5093341A (en) * | 1987-12-17 | 1992-03-03 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine derivatives useful as antithrombolytic agents |
US5064838A (en) * | 1988-01-21 | 1991-11-12 | Merrell Dow Pharmaceuticals | 1,4-disubstituted-piperidinyl compounds as pain relievers |
DE3888340T2 (de) * | 1988-01-21 | 1994-06-30 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit. |
KR890012971A (ko) * | 1988-02-10 | 1989-09-20 | 원본미기재 | 심장혈관 항히스타민제 및 분비억제제로서의 n-치환된-아릴알킬 및 아릴알킬렌 아미노헤테로사이클릭 화합물 |
US4921863A (en) * | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
AU629534B2 (en) * | 1988-02-24 | 1992-10-08 | A.H. Robins Company, Incorporated | New methods and related compounds |
ZA891901B (en) * | 1988-03-17 | 1989-11-29 | Merrell Dow Pharma | Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy |
US5254556A (en) * | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
US5070087A (en) * | 1989-05-08 | 1991-12-03 | A. H. Robins Company, Incorporated | Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents |
US5106855A (en) * | 1989-12-20 | 1992-04-21 | Merrell Dow Pharmaceuticals Inc. | Method for the treatment of glaucoma |
US5116846A (en) * | 1990-03-28 | 1992-05-26 | Du Pont Merck Pharmaceutical Company | N-aralkyl piperidine derivatives as psychotropic drugs |
ATE114467T1 (de) * | 1990-06-01 | 1994-12-15 | Merrell Dow Pharma | (+)-alpha-(2,3 dimethoxyphenyl)-1-(2- (fluorophenyl)ethyl>-4-piperidinmethanol. |
EP0661266A1 (en) * | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Substituted cyclic amine compounds as 5HT2 antagonists |
US5618824A (en) * | 1994-03-09 | 1997-04-08 | Merrell Pharmaceuticals Inc. | Treatment of obsessive-compulsive disorders with 5-HT2 antagonists |
IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
-
1991
- 1991-04-30 AT AT91910548T patent/ATE114467T1/de not_active IP Right Cessation
- 1991-04-30 HU HU9203779A patent/HU213271B/hu unknown
- 1991-04-30 WO PCT/US1991/003036 patent/WO1991018602A1/en active IP Right Grant
- 1991-04-30 DK DK91910548.6T patent/DK0531410T3/da active
- 1991-04-30 AU AU79509/91A patent/AU652759B2/en not_active Expired
- 1991-04-30 KR KR1019920703050A patent/KR100211713B1/ko not_active IP Right Cessation
- 1991-04-30 ES ES91910548T patent/ES2067937T3/es not_active Expired - Lifetime
- 1991-04-30 JP JP3510161A patent/JP2869512B2/ja not_active Expired - Lifetime
- 1991-04-30 DE DE69105501T patent/DE69105501T2/de not_active Expired - Lifetime
- 1991-04-30 CA CA002083698A patent/CA2083698C/en not_active Expired - Lifetime
- 1991-04-30 EP EP91910548A patent/EP0531410B1/en not_active Expired - Lifetime
- 1991-07-26 US US07/736,194 patent/US5134149A/en not_active Expired - Lifetime
-
1992
- 1992-11-25 FI FI925342A patent/FI95370C/sv active
- 1992-11-30 NO NO924619A patent/NO179250C/no not_active IP Right Cessation
-
1995
- 1995-01-13 US US08/372,694 patent/US5561144A/en not_active Expired - Lifetime
- 1995-02-16 GR GR950400305T patent/GR3015087T3/el unknown
- 1995-06-07 US US08/485,701 patent/US5700812A/en not_active Expired - Lifetime
- 1995-06-07 US US08/476,538 patent/US5721249A/en not_active Expired - Lifetime
- 1995-06-07 US US08/485,700 patent/US5700813A/en not_active Expired - Lifetime
-
1997
- 1997-10-02 US US08/942,629 patent/US5874445A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NO179250B (no) | 1996-05-28 |
CA2083698C (en) | 1997-11-04 |
EP0531410A1 (en) | 1993-03-17 |
NO924619L (no) | 1992-11-30 |
US5874445A (en) | 1999-02-23 |
ATE114467T1 (de) | 1994-12-15 |
FI95370B (sv) | 1995-10-13 |
NO924619D0 (no) | 1992-11-30 |
DE69105501D1 (de) | 1995-01-12 |
FI925342A (sv) | 1992-11-25 |
KR100211713B1 (ko) | 1999-08-02 |
AU7950991A (en) | 1991-12-31 |
US5561144A (en) | 1996-10-01 |
ES2067937T3 (es) | 1995-04-01 |
GR3015087T3 (en) | 1995-05-31 |
US5700812A (en) | 1997-12-23 |
HUT64745A (en) | 1994-02-28 |
CA2083698A1 (en) | 1991-12-02 |
DE69105501T2 (de) | 1995-04-13 |
WO1991018602A1 (en) | 1991-12-12 |
HU213271B (en) | 1997-04-28 |
AU652759B2 (en) | 1994-09-08 |
FI925342A0 (sv) | 1992-11-25 |
JPH05507482A (ja) | 1993-10-28 |
NO179250C (no) | 1996-09-04 |
KR930700103A (ko) | 1993-03-13 |
FI95370C (sv) | 1996-01-25 |
US5134149A (en) | 1992-07-28 |
EP0531410B1 (en) | 1994-11-30 |
JP2869512B2 (ja) | 1999-03-10 |
HU9203779D0 (en) | 1993-03-29 |
US5721249A (en) | 1998-02-24 |
EP0531410A4 (en) | 1993-05-26 |
US5700813A (en) | 1997-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0531410T3 (da) | (+)-alfa-(2,3-Demethoxyphenyl)-1-(2-(4-fluorphenyl)ethyl)-4-piperidinmethanol | |
SE9504661D0 (sv) | New compounds | |
DE60124684D1 (de) | Sulfonamido-substituierte verbrückte bicycloalkylderivative | |
NO983003L (no) | Vitronectin-reseptor-antagonister | |
DE69330823T2 (de) | Thiacyclische piperidinylderivate | |
DE69414398T2 (de) | Heterocyclische neurokinin-antagonisten | |
GR3036458T3 (en) | 4-imidomethyl-1- 2'phenyl-2'oxoethyl-] piperidines as serotonin 5ht 2?-antagonists, their preparation and use in therapy. | |
DK0680323T3 (da) | Synergistisk kombination med antagonistvirkning ved NK1- og Nk2-receptorer. | |
BR9708109A (pt) | Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinametanol no tratamento de distúrbios depressivos e distúrbios bipolares | |
SE9504662D0 (sv) | New compounds | |
NO20004545D0 (no) | FremgangsmÕte for fremstilling av (R)-<alfa>-(2,3- dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol | |
HUP0202145A3 (en) | The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders | |
NO964291L (no) | Fremgangsmåte for behandling av allergisk rinitt | |
BR1100532A (pt) | (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorfenil)etil]-4-pipe ridinometanol e composição contendo o mesmo |